Dakum Patrick, Kayode Gbenga Ayodele, Abimiku Alash'le, Avong Yohanna Kambai, Okuma James, Onyemata Ezenwa, Ali Taofeekat, Adekanmbi Victor, Uthman Olalekan
Institute of Human Virology.
International Research Centre of Excellence, Institute of Human Virology, Nigeria, Maina Court, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Medicine (Baltimore). 2019 Apr;98(15):e15024. doi: 10.1097/MD.0000000000015024.
Hypertension is one of the common medical conditions observed among patients aged 50 years and elder living with HIV (EPLWH) and to date no systematic review has estimated its global prevalence.
To conduct a systematic review to estimate the global prevalence of hypertension among EPLWH.
PubMed/MEDLINE, Embase, the Cochrane Library, and Global Health databases for relevant publications up till May 25, 2018.
Observational studies (cohort or cross-sectional studies) that estimated the prevalence of hypertension among EPLWH.
Required data were extracted independently by three reviewers and the main outcome was hypertension prevalence among EPLWH.
The 24 (n = 29,987) eligible studies included were conducted in North America, Europe, Africa, and Asia. A low level bias threat to the estimated hypertension prevalence rates was observed. The global prevalence of hypertension among EPLWH was estimated at 42.0% (95% CI 29.6%-55.4%), I = 100%. The subgroup analysis showed that North America has the highest prevalence of hypertension 50.2% (95% CI 29.2% -71.2%) followed by Europe 37.8% (95% CI 30.7%-45.7%) sub-Saharan Africa 31.9% (95% CI 18.5% -49.2%) and Asia 31.0% (95% CI 26.1%-36.3%). We found the mean age of the participants explaining a considerable part of variation in hypertension prevalence.
This study demonstrated that two out of five EPLWH are hypertensive. North America appears to have the highest prevalence of hypertension followed by Europe, sub-Saharan Africa (SSA) and Asia respectively. Findings from this study can be utilized to integrate hypertension management to HIV management package. (Registration number: CRD42018103069).
高血压是50岁及以上感染艾滋病毒的老年患者（EPLWH）中常见的病症之一，迄今为止，尚无系统评价估计其全球患病率。
进行系统评价，以估计EPLWH中高血压的全球患病率。
截至2018年5月25日，检索PubMed/MEDLINE、Embase、Cochrane图书馆和全球卫生数据库，获取相关出版物。
估计EPLWH中高血压患病率的观察性研究（队列研究或横断面研究）。
由三位审阅者独立提取所需数据，主要结果是EPLWH中的高血压患病率。
纳入的24项（n = 29987）符合条件的研究在北美、欧洲、非洲和亚洲进行。观察到对估计的高血压患病率存在低水平偏倚威胁。EPLWH中高血压的全球患病率估计为42.0%（95%CI 29.6%-55.4%），I = 100%。亚组分析显示，北美高血压患病率最高，为50.2%（95%CI 29.2%-71.2%），其次是欧洲，为37.8%（95%CI 30.7%-45.7%），撒哈拉以南非洲为31.9%（95%CI 18.5%-49.2%），亚洲为31.0%（95%CI 26.1%-36.3%）。我们发现参与者的平均年龄在很大程度上解释了高血压患病率的差异。
本研究表明，五分之二的EPLWH患有高血压。北美高血压患病率似乎最高，其次是欧洲、撒哈拉以南非洲（SSA）和亚洲。本研究结果可用于将高血压管理纳入艾滋病毒管理方案。（注册号：CRD42018103069）
